The Upjohn Co.

Pharmacia & Upjohn Company

Other

Sugen Incorporated

Pfizer Corporation

Agouron Pharmaceuticals, Inc.

Walter Morozowich

Ping Gao

Malcolm Wilson Moon

Marcel Koenig

Michael John Hawley

Mark Peter Warchol

Peng Cho Tang

Patrick J Lennon

Dominique Bonafoux

Sergey Gregory Wolfson

Ivan Richards

Sue K Cammarata

Craig D Wegner

Mark Kontny

Karen Patrice Kolbasa

Alice C Martino

Ashley H Bates

E John Lee

Satish Kumar Singh

Youmin Wang

The compound 2-[(1R)-3-(diisopropylamino)-1-phenylpropyl]-4-(trifluoromethyl) phenol may be used to prepare the compound (3R)-3-[2-hydroxy-5-(trifluoromethyl)phenyl]-N,N-diisopropyl-N-methyl-3-phenylpropan-1-aminium bromide by reaction with methyl bromide.

Phenol derivative

Pharmaceutical compositions suitable for oral administration comprising paclitaxel, a solvent, a surfactant, a substituted cellulosic polymer, and optionally but preferably a P-glycoprotein inhibitor. The composition may further comprise a diglyceride or mixture of diglyceride and monoglyceride. The composition generates a supersaturated paclitaxel microemulsion upon contact with water resulting in improved oral bioavailability of paclitaxel.

Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability

The present invention is directed to prodrugs of certain 3-(pyrrol-2-yl-methylidene)-2-indolinone derivatives that modulate the activity of protein kinases ('PKs'). Pharmaceutical compositions comprising these compounds, methods of treating diseases related to abnormal PK activity utilizing pharmaceutical compositions comprising these compounds and methods of preparing them are also disclosed.

Prodrugs of 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives

Disclosed is a non-sustained release pharmaceutical tablet composition which comprises a rapidly precipitating drug in an amount from about 5 to about 60% and at least one member selected from the group consisting of a binder in an amount of from about 2 to about 25% and a superdisintegrant in an amount from about 6 to about 40% where the rapidly precipitating drug, 'binder' and superdisintegrant are mixed and compressed into a tablet without heating, solvent or grinding.

Tablet formation

The present invention is directed to Mannich base prodrugs of certain 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives that modulate the activity of protein kinases ('PKs'). Pharmaceutical compositions comprising these compounds, methods of treating diseases related to abnormal PK activity utilizing pharmaceutical compositions comprising these compounds and methods of preparing them are also disclosed.

Mannich base prodrugs of 3-(pyrrol-2-yl-methylidene)-2-indolinone derivatives

The present invention is directed to 1-pyrrolidin-1-ylmethyl-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives that modulate the activity of protein kinases ('PKs'). Pharmaceutical compositions comprising these compounds, methods of treating diseases related to abnormal PK activity utilizing pharmaceutical compositions comprising these compounds and methods of preparing them are also disclosed.

1-(Pyrrolidin-1-ylmethyl)-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives

The present invention concerns novel pharmaceutically active compounds, pharmaceutical compositions containing the same, the compounds for use as medicaments, and use of the compounds for the manufacture of specific medicaments. The present invention also concerns a method of treatment involving administration of the compounds. Specifically, the compounds are pharmaceutically acceptable salts of tolterodine or hydroxytolterodine, wherein the salt is of an acid selected from the group consisting of aliphatic mono- and dicarboxylic acids comprising from 7 to 24 carbon atoms, alkanedisulfonic acids comprising from 2 to 4 carbon atoms, naphthoic acid derivatives comprising from 11 to 27 carbon atoms, maleic acid and fumaric acid.

Tolterodine salts

The present invention provides an emulsion formulation with high oral bioavailability containing lecithin as an emulsifier and solubilizing agent to achieve a high loading of the pyranone compound of formula I

Pharmaceutical emulsions for retroviral protease inhibitors

Novel quaternary ammonium compounds of the formulaand any stereoisomers thereof, wherein R, Rand Rindependently represent C-Calkyl, optionally substituted with phenyl or hydroxyl, or both, and wherein any two of R, Rand Rmay form a ring together with the quaternary ammonium nitrogen; Rrepresents &#x2014;H, &#x2014;CH, or &#x2014;CO&#x2014;R, wherein Rrepresents &#x2014;(C-Calkyl), &#x2014;(C-Calkoxy), or &#x2014;NRR, wherein Rand Rindependently represent &#x2014;H or &#x2014;(C-Calkyl); R, Rand Rindependently represent &#x2014;H, &#x2014;OCH, &#x2014;OH, &#x2014;CONH, &#x2014;SONH, &#x2014;F, &#x2014;Cl, &#x2014;Br, &#x2014;I, &#x2014;CF, or &#x2014;(C-Calkyl), optionally substituted with one or two &#x2014;OH, &#x2014;(C-Calkoxy), &#x2014;COOH, or &#x2014;CO&#x2014;O&#x2014;(C-Calkyl); and Xrepresents an anion of a pharmaceutically acceptable acid, the compounds for use as medicaments, use of the compounds for the manufacture of specific medicaments, and pharmaceutical compositions comprising the compounds. The present invention also concerns a method of treatment involving administration of the compounds.

Quaternary ammonium compounds

The present invention is directed to prodrugs of certain 3-(pyrrol-2-yl-methylidene)-2-indolinone derivatives that modulate the activity of protein kinases (&ldquo;PKs&rdquo;). Pharmaceutical compositions comprising these compounds, methods of treating diseases related to abnormal PK activity utilizing pharmaceutical compositions comprising these compounds and methods of preparing them are also disclosed.

The present invention is directed to Mannich base prodrugs of certain 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives that modulate the activity of protein kinases (&ldquo;PKs&rdquo;). Pharmaceutical compositions comprising these compounds, methods of treating diseases related to abnormal PK activity utilizing pharmaceutical compositions comprising these compounds and methods of preparing them are also disclosed.

Mannich base prodrugs of 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives

The present invention provides a novel pharmaceutical composition based on the use of a particular oil phase which comprises a lipophilic, pharmaceutically active agent, a mixture of diglyceride and monoglyceride in a ratio of from about 9:1 to about 6:4 by weight (diglyceride:monoglyceride) wherein the diglyceride and monoglyceride are mono- or di- unsaturated fatty acid esters of glycerol having sixteen to twenty-two carbon chain length, one or more pharmaceutically acceptable solvents, and one or more pharmaceutically acceptable surfactants. The composition is in a form of self-emulsifying formulation which provides high concentration and high oral bioavailability for lipophilic compounds.

Self-emulsifying formulation for lipophilic compounds

The present invention is directed to 1-pyrrolidin-1-ylmethyl-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives that modulate the activity of protein kinases (&ldquo;PKs&rdquo;). Pharmaceutical compositions comprising these compounds, methods of treating diseases related to abnormal PK activity utilizing pharmaceutical compositions comprising these compounds and methods of preparing them are also disclosed.

1-(pyrrolidin-1-ylmethyl)-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives

The present invention provides a novel pharmaceutical composition based on the use of a particular amount of basic amine which comprises a pyranone compound as a pharmaceutically active agent, a basic amine in an amount of from about 0.1% to about 10% by weight of the total composition, one or more pharmaceutically acceptable solvents, and one or more pharmaceutically acceptable surfactants. In addition, the composition may further comprises one or more pharmaceutically acceptable oils. The composition is in a form of self-emulsifying formulation which provides high concentration and high oral bioavailability for lipophilic pyranone compounds.

Growing community of inventors

Kalamazoo, MI, United States of America

Walter Morozowich